

# **SERVIER BIOINNOVATION**

## Our Team



**Christian Schubert, PhD, MSc** Global Head, External Innovation Director, Servier BioInnovation Tel: +1.857.354.1779

Cynthia Wang, MBA, MSc

Director, BD & Licensing Servier BioInnovation Asia

Tel: + 86 13910100149 cynthia.wang@servier.com

## **Our Areas of Interest**

Research collaborations to early clinical development (best modality for right target in right patient at right time)

christian.schubert@servier.com		Medical need	Biology
Rekha Paleyanda, PhD Head, US Business Development & Licensing; Director, Servier BioInnovation Tel: +1.857.354.1771 rekha.paleyanda@ervier.com	CARDIOLOGY	Heart failure, atrial fibrillation	Pathophysiology and regeneration
Michele Bernier, MBA Operations Manager	METABOLISM	T2D, NASH, diabetic kidney and liver disease	Insulin resistance, inflammation, fibrosis
Tel: +1.857.354.1782 <u>michele.bernier@ervier.com</u> Marion Paolini, PhD External Innovation Manager	ONCOLOGY	Hematological and solid tumors	Apoptosis, immuno-oncology (T-cell focus)
Tel: +1.857.354.1783 marion.paolini@servier.com	IMMUNO- INFLAMMATORY	Autoimmune disease, including Lupus, Sjögren, systemic sclerosis	Cytokine and immune regulation
Chu-Ya (Jennifer) Yang, PhD Director, Search and Evaluation Servier BioInnovation Asia Tel: +86 185 1511 6225 jennifer.yang@servier.com	CNS	Neurodegeneration	Proteinopathies, neuroinflammation

# Your one-stop shop for innovation!

#### Servier's Unique Value Proposition as a Partner

An independent pharmaceutical group, governed by a non-profit foundation, ensuring continuity, long-term vision and commitment to partners

Broad geographical footprint almost 150 countries, strong EU and emerging market, and growing US presence

Strong patient focus, treating over 100M patients daily

Recognized chemistry, CMC, regulatory, development, and commercial excellence, particularly in cardiometabolism and oncology

Strong reputation in the scientific community, passionate and dedicated people

Focused partner, prioritizing collaborations and dedicating resources to ensure mutual success

#### Assets and technologies of interest

• We are interested in all types of innovative, first- or best-in-class products, that bring true therapeutic impact to areas of unmet medical need

#### Deal types in which we engage

- Creative deal structures that generate true partnerships
- Research collaborations, co-development, in-licenses
- · World-wide, regional, or local deals

### What we bring to our partners

- World-class R&D capabilities, 3 research centers
- Reinvest 25% of revenues into R&D
- 15 clinical trial centers for clinical development
- 16 drug manufacturing sites across the world
- Commercial operations in over 90 countries worldwide
- Alliance management expertise with an extensive network of alliances

Servier Annual Report: https://servier.com/en/annual-report-2018-2019/

### Servier BioInnovation: Your one-stop shop for innovation

- We serve as the 'one-stop shop' for innovators in North America and Asia, sourcing R&D opportunities and expediting BD&L activities
- Our key stakeholders include world-class academic researchers, technology transfer and development offices, non-profit foundations, patient advocacy organizations, company builders, venture capitalists and strategic biotechnology and pharma partners
- We are responsible for increasing the Group's visibility, attracting talent and establishing R&D partnerships and managing alliances, through targeted representation in the world's top biomedical innovation centers
- We have been present in the United States (Cambridge, MA) and Asia (Beijing) since 2018